Aems
Denver, US · Founded 2019 · Delaware corporation
Find your way into Aems
Sign up to see every warm intro you have to Aems
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aems team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AEMS Corp solves viscosity problems in liquid formulations using proprietary and patented methods and an automated high-throughput, microscale lab, focusing primarily on next-generation pharmaceuticals such as high-concentration injectable biologics and siRNA therapeutics. It also formulates antimicrobial and edible sprayable coatings and other molecular systems for companies whose product development is blocked by viscosity challenges.
Founders & leadership
Aems was founded in 2019 by Nicholas Collella, W. Scott Compel, Alexander R. Hendricks, and Nick Colella.
Board
Reported raises · per SEC filings
Form D private placements$820K disclosed across 5 rounds · 2020–2026
▶$95KraisedSep 2026 · 3 investors · Other TechnologyRule 506(b)
- William CompelExecutive Officer, Director
- Nick TraggisDirector
- Michael ChangDirector
- Offering amount
- $1M
- Amount sold
- $95K
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedMar 2026 · 4 investors · Other TechnologyRule 506(b)
- William S. CompelExecutive Officer, Director
- Michael ChangDirector
- Nick TraggisDirector
- Offering amount
- $700K
- Amount sold
- $100K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$225KraisedMay 2025 · 4 investors · Other TechnologyRule 506(b)
- Michael ChangDirector
- William CompelExecutive Officer, Director
- Nick TraggisDirector
- Offering amount
- $500K
- Amount sold
- $225K
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedOct 2023 · 4 investors · Other TechnologyRule 506(b)
- Michael ChangDirector
- Nicholas CollellaDirector
- William CompelExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$150KraisedAug 2020 · 2 investors · Other TechnologyRule 506(b)
- Nicholas J. ColellaDirector
- William Scott CompelExecutive Officer, Director
- Offering amount
- $200K
- Amount sold
- $150K
- Minimum investment
- $10K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Aems.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Centers for Disease Control and Prevention (CDC)Centers for Disease Control and Prevention | Phase I | 2022 | $200K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Aems do?
- AEMS Corp solves viscosity problems in liquid formulations using proprietary and patented methods and an automated high-throughput, microscale lab, focusing primarily on next-generation pharmaceuticals such as high-concentration injectable biologics and siRNA therapeutics. It also formulates antimicrobial and edible sprayable coatings and other molecular systems for companies whose product development is blocked by viscosity challenges.
- Who founded Aems?
- Aems was founded by Nicholas Collella, W. Scott Compel, Alexander R. Hendricks, Nick Colella in 2019.
- How much funding has Aems raised?
- Aems has disclosed $820K raised across 5 rounds.
- Where is Aems headquartered?
- Aems is headquartered in Denver, US.
